Search Results for "Thyroid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Thyroid. Results 21 to 30 of 84 total matches.

Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
pancreatitis and acute gall bladder disease ▶ Thyroid C-cell tumors reported in animals; contraindicated ...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-3   doi:10.58347/tml.2024.1708c |  Show IntroductionHide Introduction

Estetrol/Drospirenone (Nextstellis) - A New Combination Oral Contraceptive

   
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021  (Issue 1627)
serum concentrations of some systemic corticosteroids, and it can increase thyroid-binding globulin ...
The FDA has approved a combination oral contraceptive containing the estrogen estetrol and the progestin drospirenone (Nextstellis – Mithra/Mayne). Estetrol is the first new estrogen to become available in the US in 50 years. Drospirenone is available alone (Slynd) and in combinations with the estrogen ethinyl estradiol for prevention of pregnancy.
Med Lett Drugs Ther. 2021 Jun 28;63(1627):101-2 |  Show IntroductionHide Introduction

Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Mar 09, 2009  (Issue 1307)
in the alemtuzumab group included autoimmune-related thyroid dysfunction in 49 patients (22.7%), immune ...
Alemtuzumab (Campath), a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ transplants, is now also being tried off-label for treatment of relapsing multiple sclerosis (MS).
Med Lett Drugs Ther. 2009 Mar 9;51(1307):17-8 |  Show IntroductionHide Introduction

Two New GLP-1 Receptor Agonists for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Nov 10, 2014  (Issue 1455)
, and duration of these effects vary within the class. GLP-1 receptor agonists have been shown to cause thyroid ...
Two new injectable GLP-1 (glucagon-like peptide-1) receptor agonists, dulaglutide (Trulicity [trū li si tee] – Lilly) and albiglutide (Tanzeum [tan' zee um] – GSK), have been approved by the FDA for once-weekly treatment of type 2 diabetes. Other available GLP-1 receptor agonists include exenatide, which is approved for injection twice daily (Byetta) or once weekly (Bydureon), and liraglutide (Victoza), which is injected once daily.
Med Lett Drugs Ther. 2014 Nov 10;56(1455):109-11 |  Show IntroductionHide Introduction

Liraglutide (Saxenda) for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
. Thyroid C-cell tumors have been reported in rodents given liraglutide, and the FDA has required a boxed ...
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide, previously approved by the FDA for treatment of type 2 diabetes as Victoza, has now also been approved at a higher dose as Saxenda (Novo Nordisk) for chronic weight management in adults with a BMI ≥30, or a BMI ≥27 with a weight-related comorbidity such as hypertension, dyslipidemia, or diabetes.
Med Lett Drugs Ther. 2015 Jun 22;57(1471):89-90 |  Show IntroductionHide Introduction

Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017  (Issue 1529)
gastroparesis. GLP-1 receptor agonists have been shown to cause thyroid C-cell tumors in animals ...
The FDA has approved Xultophy 100/3.6 (Novo Nordisk), a fixed-ratio combination of insulin degludec and the GLP-1 (glucagon-like peptide-1) receptor agonist liraglutide, for once-daily treatment of adults with type 2 diabetes inadequately controlled on basal insulin (<50 units daily) or liraglutide (≤1.8 mg daily).
Med Lett Drugs Ther. 2017 Sep 11;59(1529):147-9 |  Show IntroductionHide Introduction

Extended-Release Exenatide (Bydureon) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Mar 19, 2012  (Issue 1386)
taking exenatide; whether they were caused by the drug or the disease is not clear. Thyroid C-cell ...
The FDA has approved a once-weekly extendedrelease formulation of exenatide (Bydureon – Amylin), an injectable glucagon-like peptide-1 (GLP-1) receptor agonist, for treatment of type 2 diabetes.
Med Lett Drugs Ther. 2012 Mar 19;54(1386):21-3 |  Show IntroductionHide Introduction

Opdualag for Metastatic Melanoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023  (Issue 1668)
, rash, arthralgia, hypothyroidism or thyroiditis, diarrhea, and vitiligo were reported in ≥10 ...
Opdualag (BMS), a fixed-dose combination of two immune checkpoint inhibitors — nivolumab (Opdivo), a programmed death receptor-1 (PD-1) inhibitor, and relatlimab-rmbw, a lymphocyte-activation gene-3 (LAG-3) blocking antibody — has been approved by the FDA for treatment of unresectable or metastatic melanoma in patients ≥12 years old. Relatlimab, which is only available in combination with nivolumab, is the first LAG-3 blocking antibody to become available in the US. Immune checkpoint inhibitors, including the anti-CTLA-4 antibody ipilimumab (Yervoy) and the PD-1 inhibitors...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):e19-20   doi:10.58347/tml.2023.1668g |  Show IntroductionHide Introduction

Tirzepatide (Zepbound) for Obstructive Sleep Apnea

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025  (Issue 1722)
a risk of thyroid C-cell tumors (based on animal data; no corroborating human data ...
The injectable glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide (Zepbound) has been approved by the FDA for treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. It is the first drug to be approved in the US for this indication. Zepbound is also approved for chronic weight management in adults with obesity and in those who are overweight and have at least one weightrelated comorbidity. Tirzepatide is also available as Mounjaro for treatment of type 2 diabetes.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):29-31   doi:10.58347/tml.2025.1722c |  Show IntroductionHide Introduction

Oral Semaglutide (Rybelsus) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Oct 21, 2019  (Issue 1583)
agonists (not lixisenatide), the label of semaglutide includes a boxed warning about a risk of thyroid C ...
An oral formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Rybelsus – Novo Nordisk) has been approved by the FDA for once-daily treatment of type 2 diabetes in adults. Semaglutide, which has been available in a subcutaneously-injected formulation (Ozempic) since 2017, is the first GLP-1 receptor agonist to become available for oral administration; the 4 other GLP-1 receptor agonists currently available in the US are administered by subcutaneous (SC) injection.
Med Lett Drugs Ther. 2019 Oct 21;61(1583):166-8 |  Show IntroductionHide Introduction